Trial: 201907126

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Phase

II

Principal Investigator

Van Tine, Brian

Disease Site

Soft Tissue

Learn more about this study at: clinicaltrials.gov